Baxter BioPharma Solutions
Content From Baxter BioPharma Solutions
-
Considerations and Options for Prefilled Syringes
Learn the options available for prefilled syringes and some considerations for developing and manufacturing the product.White Papers / Tech Papers Released on 03.16.2021
-
Seasonal Vaccine Manufacturing
There are three areas to evaluate when selecting an outsourcing partner for seasonal vaccine manufacturing.White Papers / Tech Papers Released on 02.12.2021
-
Leak Rate Testing for Freeze Dryers: A Scientific Approach
Assurance of the vacuum integrity of freezedryers used for the manufacture of sterile pharmaceutical products is essential for GMP operations.White Papers / Tech Papers Released on 03.08.2019
-
Pharmaceutical Development for ADCs: Not as Simple as ABC
...White Papers / Tech Papers Released on 03.08.2019
-
BIOSIMILARS: Global Terminology, Strategy & Pathways
Download the Global Terminology, Strategy & Pathways PosterPosters Released on 03.08.2019
-
Enhanced Delivery Options for Injectables
Download the Enhanced Delivery Options Poster.Posters Released on 03.08.2019
-
Considerations for Development of Lyophilized Biosimilar
This whitepaper discusses considerations for development of a lyophilized biosimilar, as well as a biosimilar case study.White Papers / Tech Papers Released on 11.01.2018
-
Your CMO for Sterile Injectables
85+ years of expertise in process and formulation development, technology transfer, and parenteral manufacturing.Videos Released on 10.19.2018
-
Baxter's BioPharma Solutions Business Recognized with ViE Award for Fifth Time
...News Releases Released on 07.06.2018
-
Capabilities Brochure - The Promise of Science Maximized
...Literature / Brochures Released on 07.06.2018
-
Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility
When different drug products are produced in shared facilities, the potential for cross contamination is always a concern.White Papers / Tech Papers Released on 07.06.2018
Related Content
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News | Parenterals
Baxter Biopharma Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine
Manufacturing to take place at Baxter’s state-of-the-art Halle/Westfalen, Germany facility.Tim Wright, Editor, Contract Pharma 03.09.21
-
Bio News | Breaking News | Industry News
High Purity New England Bolsters Biopharma Solutions Services
Launches customizable cell culture bioreactor line.Tim Wright, Editor, Contract Pharma 02.25.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News | Parenterals
Baxter, Novavax Ink Sterile Manufacturing Agreement
CMO Baxter will help increase commercial production and promote access to Novavax' Covid-19 vax in UK and European markets.Contract Pharma Staff 01.11.21
-
Aseptic Processing | Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Fill/Finish | Industry News | Injectables | Lyophilization | Parenterals
Baxter Invests $50M to Expand Sterile Fill/Finish Manufacturing Operations
Construction currently underway; expected to be completed in 2021.Contract Pharma Staff 11.24.20
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News
Sensorion and Novasep Sign Agreement
Covers the development and manufacturing of AAV vectors, a key step for Sensorion’s gene therapy programs.Contract Pharma Staff 11.03.20
-
Breaking News | Collaborations & Alliances | Drug Development
AbbVie, I-Mab Enter Global Immuno-Oncology Alliance
AbbVie to pay as much as $1.74 billion for Lemzoparlimab, one of I-Mab's leading drug candidates for the treatment of multiple cancers.Contract Pharma Staff 09.04.20
-
Breaking News | R&D
Processa Pharmaceutical Enters Licensing Agreement with Elion Oncology
Will develop, manufacture and commercialize eniluracil (PCS6422) globally.Contract Pharma Staff 08.27.20
-
Breaking News | Drug Development | Industry News
Oncology Venture Acquires PARP Inhibitor Program
Now has full ownership of 2X-121, which is being developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19.Contract Pharma Staff 07.13.20
-
Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News
Merck Inks $425M Oncology Deal with Foghorn Therapeutics
To discover and develop novel oncology therapeutics against transcription factor target.Contract Pharma Staff 07.08.20
-
Breaking News | Drug Development | Industry News
Oncology Venture Out-Licenses Clinical Assets to Smerud
Smerud will advance development of LiPlaCis in late stage metastatic breast cancer and 2X-111 in glioblastoma multiforme.Contract Pharma Staff 06.29.20
-
APIs | cGMP Manufacture | Clinical Trials | Supply Chain
Evaluating Pharma Amid COVID-19
Dr. Ural of Ernst & Young LLP discusses market dynamics, enduring therapeutic areas, near term M&A, and how industry can use this time for transformationKristin Brooks, Contract Pharma 05.18.20
-
cGMP Manufacture | Clinical Trials | Drug Development | Information Technology | R&D
COVID-19’s Long-Term Impact on Drug Development: The New Pragmatism
The rise of new tools and approaches, an increase in regulatory responsibility, and the need for speed.Paul Bridges SVP Worldwide Head Regulatory & Access, Parexel and Sheela Hegde, Partner and Managing Director, Health Advances 05.18.20
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
bluebird bio Amends CAR-T Collaboration
Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-U.S. territoriesContract Pharma Staff 05.18.20
-
Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
Skyhawk Therapeutics, Merck Expand RNA Alliance
Aims to discover and develop novel small molecules that modulate RNA splicing for autoimmune and metabolic diseasesContract Pharma Staff 05.13.20
-
Breaking News | Collaborations & Alliances
AbbVie, Scripps Collaborate on New Therapeutics
To develop new therapies for a range of diseases, including areas of oncology, immunology, neurology and fibrosis.12.09.19
-
Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
Harpoon, Abbvie Expand Immunotherapy Alliance
New license and option agreement represents a potential transaction value of as much as $510 million11.21.19
-
Breaking News | Industry News
Vineti, WuXi AppTec Ink Personalized Therapy Management Platform Pact
To combine Vineti's ordering and traceability platform with WuXi's manufacturing facilities to provide end-to-end solution11.05.19
-
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement
Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipeline10.02.19
-
Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
Continued and Consistent Investment in Manufacturing Facilities
As companies move their cell and gene therapies through the development process, supporting larger Phase III trials and commercial launches will be a challengeRyan Carpentier, Executive Director of Business Development, Cryoport 09.23.19
-
Clinical Trials
Gene Therapy Trials
Applications and the limitations of real-world data.Karen Ooms, Executive Vice President and Head of Statistics, Quanticate 09.16.19
-
Biologics, Proteins, Vaccines | Cold Chain Management | Drug Development | Supply Chain
CAR T for Large Tumors: The Next Frontier?
Ryan Carpentier of Cryoport discusses the successes and the challenges these exciting new therapies presentRyan Carpentier, Executive Director of Business Development at Cryoport 09.10.19
-
Breaking News | Drug Development | Industry News
Thermo, Lilly Enter Companion Diagnostic Pact
Thermo retains rights to commercialize the test in all markets and will submit a supplemental premarket approval to FDA09.09.19
-
Trials & Filings
BeiGene’s Tislelizumab Achieves Positive Phase II Results
Investigational anti-PD-1 antibody aims to treat Chinese patients with relapsed/refractory classical Hodgkin’s lymphoma07.18.19
-
Pricing Headwinds
Generic firms see red; CDMOs stay resilientS Harachand, Contributing Editor 07.17.19
-
Rawcliffe to Succeed Noble as Adaptimmune CEO
Noble will transition to become a Non-Executive Director07.16.19
-
Collaborations & Alliances | Drug Development
Loxo Oncology Enters Strategic Pact with AmoyDx, PREMIA
To provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-29206.24.19
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Baxter, Oasmia Ink Apealea Commercial Mfg. Pact
Apealea will be manufactured at Baxter’s cytotoxic manufacturing site in Germany12.07.18
-
Your CMO for Sterile Injectables
85+ years of expertise in process and formulation development, technology transfer, and parenteral manufacturing.
-
-
Breaking News | Industry News | Injectables
Baxter Completes $625M Purchase of Claris Injectables
Broadens Baxter’s presence in the generic pharmaceuticals space07.31.17
-
APIs | Biosimilars | Drug Delivery | Drug Development | Fill/Finish | Formulation Development | Lyophilization | Parenterals | Supply Chain
Parenteral Outsourcing Trends
Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parenteral dosage development and manufacturing marketTim Wright, Editor 03.09.16
-
Baxter BioPharma Solutions Wins the 2016 ISPE Facility of the Year Awards (FOYA)
In the Operational Excellence Category
-
Bioassay Development | Breaking News | Capsules | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Inspections | Lyophilization | Methods Development | Process Development | Regulatory Affairs | Toxicology
-
APIs | Biologics, Proteins, Vaccines | Biosimilars | Breaking News | Industry News | Lyophilization | Parenterals
Report Says Lyo-Market to Reach $4.8B in 2020
Attributes growth to rapidly developing biopharma industry and increase in CMOs globally12.01.14
-
Chemistry | Cleaning Validation | Clinical Trials | Cytotoxics and High Potency Manufacturing | Drug Development | Fill/Finish | Formulation Development | Logistics | Process Validation | Serialization | Supply Chain | Validation
Next-Gen ADCs: Collaborating to Improve Supply Chains for Development and Technology
A look into today’s ADC landscape and how collaboration aims to address ADC customer challenges.Dr. Cynthia Wooge and Dr. Jyothi Swamy , SAFC 11.13.14
-
Analytical Services | APIs | Aseptic Processing | Bioanalytical Services | Bioassay Development | Capsules | Chemistry | Cleaning Validation | Clinical Trials | Drug Development | Drug Discovery | Excipients | Extractables and Leachables | Facilities | Fill/Finish | Formulation Development | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Process Development | Serialization | Supply Chain | Toxicology | Validation
Contract Pharma’s 15th Anniversary Retrospective: Then & Now
A look back at the pharma/biopharma industry and outsourcing.Kristin Brooks, Contract Pharma 10.14.14
-
Breaking News | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Lyophilization | Process Development | Supply Chain | Validation
SAFC, Baxter BioPharma Partner for ADC Offering
Will align conjugation and manufacture of drug linkers with sterile fill/finish services09.25.14
-
Supply Chain | Validation
Baxter BioPharma Solutions and SAFC Collaborate on Complete ADC Offering
Baxter ’s BioPharma Solutions business and SAFC have established a collaborative manufacturing agreement
-
Breaking News | Capsules | Drug Delivery | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Logistics | Lyophilization | Process Development
Report States CMOs Should Ramp Up Marketing Efforts
Contract renewal relatively low at 40 to 50% across all product types11.21.13
-
Logistics | Supply Chain
CMO Market Report
What’s the way ahead for finished dose formulation providers?Aiswariya Chidambaram, Frost & Sullivan 10.09.13
-
Breaking News | Fill/Finish | Lyophilization | Promotions & Moves
-
Analytical Services | APIs | Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines | Capsules | Chemistry | Clinical Trial Materials | Cytotoxics and High Potency Manufacturing | Drug Delivery | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Injectables | Lyophilization | Methods Development | Process Development | R&D | Scale-up/Technology Transfer | Solid Dosage/Semi-solids | Supply Chain | Toxicology | Vials
ADCs and Outsourcing
Fortune and opportunity in a burgeoning class of therapiesTom Spurgeon, Contract Pharma 09.06.12
-
Biologics, Proteins, Vaccines | Biosimilars | Clinical Trials | CRO News | GMPs/GCPs | Information Technology | Inspections | Preclinical Outsourcing | Regulatory Affairs
PPD Goes Private: What's Next?
Acquired by PE firms, the CRO looks to the futureLee Karras 12.14.11
-
Aseptic Processing | Cytotoxics and High Potency Manufacturing
The Shape of The Post-BV Market
The broader implications of Ben Venue exiting the CMO spaceL. Lee Karras 09.07.11
-
Biologics, Proteins, Vaccines | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Logistics | Lyophilization | Parenterals | Process Development
-
Breaking News | Promotions & Moves | Validation
-
Breaking News | Industry News | Lyophilization | Parenterals | Vials
-
Clinical Trials | Drug Delivery | Drug Discovery | Lyophilization | Vials
Six Essential Qualities of a Bio-Outsourcing Partner
What to look for in a Bio-CMODarren Hieber 04.03.07
-
Breaking News | Industry News | Lyophilization
-
Inspections | Lyophilization | Parenterals | Validation
Parenteral Manufacturing
The parenteral drug sector is driven by new cancer drugs and a considerable number of biologics. Veteran performers, like Baxter Biopharma, brace for growth.Tom Spurgeon 04.04.06
